Royalty Report: Drugs, Cannabis, Therapeutic – Collection: 249613

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 19

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 19

Primary Industries

  • Drugs
  • Cannabis
  • Therapeutic
  • Beverages
  • Cancer
  • Personal Care
  • Healthcare
  • Cosmetics
  • Celebrity
  • Tobacco
  • Drug Discovery
  • Central Nervous System

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 249613

License Grant
The Canadian Licensor and Licensee have agreed to collaborate to develop and manufacture a line of at least 3 co-branded topical cosmetic products formulated with a cannabinoid or cannabinoids.
License Property
Cannabis is a plant used in products for medical proposes.
Field of Use
This agreement pertains to the drug industry relating to cannabis.

IPSCIO Record ID: 249612

License Grant
The Canadian Licensor and Canadian Licensee have agreed to collaborate to develop and manufacture a line of at least 3 co-branded topical cosmetic products formulated with a cannabinoid or cannabinoids.
License Property
Cannabis is a plant used in products for medical proposes.
Field of Use
This agreement pertains to the drug industry relating to cosmetic products.

IPSCIO Record ID: 239294

License Grant
In this agreement the Licensee is to produce cannabis-infused baked goods and other edibles in Licensor’s production facility upon approval of Licensor’s Nevada Medical Marijuana Production License.
License Property
The Company (Licensor) seeks to be an innovative technology and solution company that converts the cannabis plant into medicines, therapies and treatments for a variety of ailments. The Company is developing and utilizing state of the art technologies in plant biology, cultivation and extraction techniques, combined with biotechnology, and plans to produce consistent and measurable medical-grade cannabis, cannabis concentrates and cannabinoid therapies.
Field of Use
This agreement pertains to the drug industry relating to cannabis-based therapeutic products.

IPSCIO Record ID: 279868

License Grant
The Parties have put into place a product production and R&D agreement.
License Property
Producer/Developer will produce products for the Company and jointly research and develop new methods to infuse foods, beverages, cosmetics, nutraceuticals, and topicals with cannabinoids.

Under the terms of the agreement, Producer/Developer will be responsible for product design, formulation, production, packaging and quality control.

Field of Use
The field of use if the development of cannabinoid products.

IPSCIO Record ID: 250292

License Grant
The Canadian Licensor licensed, for a five-year period, its Canadian portfolio of cannabis products to the Canadian Licensee.
License Property
The Licensor is a North American cannabis products and brands company.
Field of Use
The Licensee is a Canadian medical cannabis company.

IPSCIO Record ID: 269589

License Grant
The Israeli Licensor, the technology transfer company of the University, hereby grants the Israel Company an option to receive an exclusive, sublicensable, worldwide royalty-bearing license to Licensors interest in the Study Results in the field of Systemic and local, tran-dermal and trans-mucosal delivery of cannabinoids using Exudates based formulations.
License Property
The Feasibility Study Program relates to the development of a Cannabis patch and can the prospect of the cannabis patch be considered a platform, depending on its composition and the character of the ingredients included within it.
Field of Use
This agreement pertains to the drug industry relating to Cannabis.

IPSCIO Record ID: 282692

License Grant
The Canadian Licensee paid royalties to Licensor, a Canadian iconic rock band,  for products sold that were inspired by Licensor.
License Property
The products were cannabis products.
Field of Use
This agreement pertains to the cannabis industry.

IPSCIO Record ID: 352096

License Grant
Inventor has assigned the entire right, title, and interest in the Assigned Patent Applications, inventions and improvements therein, and Letters Patent (referred to herein collectively as the Innovation) to Assignee and to the extent Assignee grants a license of the Innovation, or any part thereof, to any third party, and receives Revenue therefrom, then Assignee agrees to pay to Assignor a percentage of Revenue received in the aggregate by Assignee from all such licensees granting rights to the Innovation, distributed by Assignee.
License Property
Assigned Patent Applications shall mean the Patent Applications listed.
Provisional Application No. 62/632,448
United States Application No. 16/612,472
Field of Use
Field of use is for the treatment of various diseases in the Medical industry.

IPSCIO Record ID: 265496

License Grant
The Canadian Company obtained an exclusive licence to exploit exclusive varieties of cannabis and access to extensive data that Licensor had gathered from thousands of its patients for over a decade.
License Property
Licensor is a research and development-driven company dedicated to patient care, scientific innovation, research and advancing the understanding of the therapeutic benefits of cannabis.
Field of Use
This agreement pertains to the drug industry relating to the cannabis market.

IPSCIO Record ID: 362604

License Grant
The Netherlands Licensor and Licensee collaborate research in respect of the Project Technology Results, Licensor Identified Targets and/or Non-Licensor Identified Targets.

Licensor hereby assigns, transfers and conveys to XXII all right, title and interest in and to the Results. Licensor shall execute and deliver to XXII such documents, instrument and other writings reasonably requested by XXII to vest all right, title and interest in the Results in XXII.

License Property
Licensor Identified Targets means Results that constitute or are based on genes, alleles and other regulatory elements that are identified by Licensor in the course of a Project (i.e. KeySeeQ output), other than publicly known regulatory elements.

Non-Licensor Identified Targets means Results that constitute or are based on genes, alleles and other regulators that are publicly known regulatory elements.

Project Technology Results means (i) any and all protocols, methods, procedures, know-how, software, inventions, technologies and/or combinations thereof, whether in electronic form or not and whether or not laid down in protocols that (A) is developed, created and/or generated by Licensor from the execution of a Project, (B) is applicable to the Field, and (C) is expressly a deliverable of a Project as further detailed in a PAS and/or is otherwise expressly agreed by the Parties prior to the commencement of a respective Project as being a Project Technology Result, unless otherwise agreed to in writing by the Parties after the commencement of a Project and (ii) any other protocols, methods, procedures or technologies that may be separately approved by the Steering Committee as Project Technology Results.

Licensor is a global leader in plant research involving high-value genetic traits and increased crop yields.

The focus of the collaboration will include
(i) Creating a cutting-edge genetic database which utilizes the results of genomic analyses of several hundred existing, exceptional hemp/cannabis plant lines for use in the acceleration of the Company’s development and licensing of uniquely characterized and improved hemp/cannabis plants;

(ii) Enhancing genetic variation to empower Licensee’s development of new and significantly improved varieties of hemp/cannabis plant lines and varieties with highly desirable cannabinoid profiles optimized for medicinal or therapeutic applications;

(iii) Creating a proprietary and industry-leading high-resolution “molecular genetic map” of the entire cannabis plant genome to facilitate rapid, cost-effective breeding of innovative varieties of hemp/cannabis plants with distinctive agronomic traits;

(iv) Analyzing the genomic sequences of multiple species of the hemp/cannabis plant and identifying shared genetic markers, allowing Licensee to develop improved commercial hemp/cannabis plant lines more rapidly than through conventional plant breeding approaches; and

(v) Initiating the rapid-cycle generation of hemp/cannabis plant lines with distinctive cannabinoid and terpene profiles to create elite lines.

Field of Use
Field means any and all use of, research regarding, and/or commercialization of hemp and/or cannabis (all versions and types of the genus Cannabis Sativa L plant), and/or any parts thereof, for any and all purposes, including but not limited to human, medical, agricultural, veterinary, therapeutic and other such purposes.

Licensor provides Licensee access to a unique suite of crop innovation platforms, including genomics, molecular genetics, trait discovery and breeding technologies.

IPSCIO Record ID: 288718

License Grant
The Company entered into an agreement with an undisclosed Licensor for the exclusive manufacturing and distribution in seven eastern U.S. states of the Binske® portfolio of products.
License Property
Binske® portfolio of products is a brand known for utilizing best-in-class proprietary strains and craft ingredients in its edibles, concentrates, vaporizers, and topicals.

The Binske® line of cannabis products are made from premium artisan ingredients, and the clinically tested medicinal cannabis strains.

Field of Use
This agreement pertains to the cannabis industry.

IPSCIO Record ID: 289077

License Grant
Pursuant to the Research Agreement, Licensee will conduct research using its algal expression technology to develop pharma-grade cannabinoids, the Project Cannabinoids.

If proof of concept is achieved, Licensee will grant the Canadian Company an exclusive, worldwide license over any use of prescription drugs that can treat diseases affecting the central nervous system using a subset of the Project Cannabinoids.

License Property
The agreement is for development of proof of concept that algae can express the Project Cannabinoids.
Field of Use
This pertains to the cannabis industry.

IPSCIO Record ID: 275601

License Grant
Through various third party processors, the Canadian Company, will provide medical cannabis products under the Sollievo label. The Company’s processing partner uses an exclusive, proprietary, and patentable formula in its medical products, paying the Company a product royalty on the wholesale of the products sold to dispensaries or delivery services. The Company seeks to expand the brand state by state through processor relationships, thereby creating a national line of data driven medical cannabis products tailored to patient’s needs.
License Property
The Company operates a growing network of physician- staffed medical cannabis clinics with a primary focus on enabling patients to improve and protect their health.
Field of Use
This agreement pertains to the cannabis industry.

IPSCIO Record ID: 372460

License Grant
Licensor of Japan grants to Licensee of the United Kingdom under the Collaboration IP, the nonexclusive right to use the same in any way whatsoever for the purpose of the Research Collaboration including to research, make, have made and use  Research Compounds for the purposes necessary to perform its obligations and exercise its rights under the Research Plan.

This agreement is for the research and early stage development of pharmaceutical preparations based upon Research Compounds (as defined below) for the treatment of CNS and cancer indications.

License Property
Licensor has intellectual property of botanical extracts from chemovars of Cannabis sativa for the treatment of CNS and cancer indications.

Research Compounds shall mean collectively, all Selected BDCs and Selected Drug Candidates. For clarity, Research Compounds shall include Synthetic Cannabinoids synthesized under the Research Plan and which subsequently become Selected BDCs and/or Selected Drug Candidates.

Botanical Drug Candidate or BDC shall mean
—  any cannabinoid from a single chemovar of a chemically and genetically characterized Cannabis sativa plant (Phytocannabinoid) at any stage of research or development made using any extraction method and in any degree of purification in which only a single cannabinoid is present in a concentration which has the potential to be therapeutically active including, without limitation, the THC fraction and the CBD fraction separately; and
—  a combination of two or more Phytocannabinoid extracts described above containing two or more Phytocannabinoids present in concentrations such that both have the potential to be therapeutically active mixed in a precise ratio i.e. the THC and CBD fractions mixed (without other fractions) in the ratio of THC CBD of 90 10. For clarity specifically excluded from the definition of BOC is any combination of the THC and CBD fractions when mixed (without other fractions) in a ratio of CBD to THC that falls inside the range of 2575 to 7525; and,
—  any biological or chemical modification of the Phytocannabinoids in above including any metabolite or degradant.

Synthetic Cannabinoid shall mean any Phytocannabinoid produced by synthetic methods either pursuant to a Research Plan (a Type 1 Synthetic Cannabinoid) or outside of the Research Collaboration but with information resulting from the Research Collaboration (Type 2 Synthetic
Cannabinoid).

Synthetic Cannabinoid Product shall mean any pharmaceutical product containing a Type 1 Synthetic Cannabinoid (Type 1 Synthetic Product) or a Type 2 Synthetic Cannabinoid (Type 2 Synthetic Cannabinoid Product).

Synthetic Molecule shall mean a synthetic molecule whose chemistry is not based on a Phytocannabiooid but which has been developed with information resulting from the Research Collaboration and for which one or more patent.

Synthetic Molecule Product shall mean any pharmaceutical product containing a Synthetic Molecule.

Field of Use
The  fields of use are neuropsychopharmacology, with special reference to schizophrenia; cannabinoid/opioid analgesic combinations; and, oncology.

The Research Field shall mean the treatment, diagnosis, prevention, or palliation of diseases, conditions, syndromes, and maladies of the central and peripheral nervous. systems of humans and animals and cancer in humans and animals.

IPSCIO Record ID: 257250

License Grant
The Israeli Licensor and the Cayman Islands Licensee hereby agree to the amendment of the License Agreement (the 'First Amendment') to amend the product definition and the royalty consideration for Over the Counter Pharmaceutical Products.
License Property
Pharmaceutical Product shall mean, with respect to each jurisdiction in which it is sold or intended for sale (the 'Applicable Jurisdiction'), any cannabis-based product, compound or medicine which under the laws of the Applicable Jurisdiction would be regulated and subject to approval and restrictions in the same manner and degree and for specific indications as an approved or registered pharmaceutical product (“Pharmaceutical-Level Regulation”), whether or not prescribed or used for that specific indication, and whether used or sold pursuant to a prescription or over the counter; provided, however, that for purposes of this Agreement (a) the following shall not be considered a “Pharmaceutical Product” (i) cannabis plants (including flowers) in their natural form; (ii) food supplements containing cannabis as part of their ingredients, unless they are subject in the Applicable Jurisdiction to Pharmaceutical-Level Regulation; (iii) cosmetic products containing cannabis as part of their ingredients, unless they are subject in the Applicable Jurisdiction to Pharmaceutical-Level Regulation; and (iv) cannabis-based toothpastes, (b) cannabis-based extracts, oils and mixtures shall not be considered a “Pharmaceutical Product”, unless and to the extent such extracts, oils or mixtures are or were subject in the Applicable Jurisdiction to Pharmaceutical-Level Regulation or have potency levels equal to or higher than an identical or substantially similar product which is subject in the Applicable Jurisdiction to Pharmaceutical-Level Regulation, and (c) notwithstanding the foregoing, in the event that identical or substantially similar cannabis-based products can be sold in any Applicable Jurisdiction as both a pharmaceutical product which is subject to Pharmaceutical-Level Regulation and as a medical or adult use cannabis product which is not subject to Pharmaceutical-Level Regulation, for purposes of this Agreement, the form of such cannabis-based product which is permitted to be sold without being subject to Pharmaceutical-Level Regulation shall not be considered a “Pharmaceutical Product”. '
Field of Use
Licensee is an early stage biopharmaceutical company engaged in the business of discovering, developing and commercializing drugs containing cannabinoids, which are based on a proprietary cannabinoid-based product platform, for the treatment of various diseases, disorders and medical conditions.

IPSCIO Record ID: 278523

License Grant
Under the terms of the agreement, the parties will develop a new product utilizing the intellectual property of Licensor and the launch of the co-branded product.
License Property
The focus is on the development, sale and distribution of hemp oil-based products that contain naturally occurring cannabinoids, including cannabidiol ('CBD') and other products containing CBD-rich hemp oil (“Legal Hemp”).
Field of Use
This agreement pertains to the cannabis industry.

IPSCIO Record ID: 249597

License Grant
In this related party agreement, the Company executed five exclusive pharmaceutical license agreements with the Company’s CEO, the Company’s CMO, three advisory board members of the Company, and an unrelated third party. These agreements provide the Company the worldwide exclusive rights to certain drug technologies and methods (and systems) for collection, processing and use of data for the dispensing of phyto-medical and botanically derived materials for consumption. The license agreements grant to the Company from the inventors the rights to develop, market, make, use, and sell certain drug formulations, which are applied to humans through the use of certain drug technology.
License Property
The Licensor parties are part of a developmental stage phyto-medical/pharmaceutical and drug discovery company that specializes in the research, development of cannabinoid and cannabinoid-based therapeutic products derived from synthetic and botanical sources, including the Cannabis “taxa” (the word “taxa” is the plural of “taxon” which defines a group of one or more populations of an organism or organisms to form a unit.)

Cannabinoids are a class of compounds derived from Cannabis plants. The two primary cannabinoids contained in Cannabis are cannabidiol, or CBD, and D9-tetrahydrocannabinol, or THC. Clinical and preclinical data suggest that CBD has positive effects on treating refractory epilepsy, FXS and arthritis and THC has positive effects on treating pain.

Field of Use
The rights granted apply to the drug industry.

IPSCIO Record ID: 235008

License Grant
Licensor hereby grants Licensee, including Licensees Affiliates,

(a) during the Term, a royalty-bearing, Territory-wide license in the Licensed Field under the Patent Rights to the Licensed Technology, as well as under the Licensed Patents, the Licensed Know-how, and the Licensed Technology, regardless of whether such Licensed Patents are actually granted, to use the Licensed Know-how and Licensed Technology and to develop and have developed, make and have made, use and have used, sell and have sold, offer for sale and have offered for sale, import and have imported, export and have exported, any and all inventions claimed in the Licensed Patents related to the Licensed Products and/or any compounds, chemicals, substrates, devices, tools, dies, molds or any other materials whatsoever that are useful in the development and/or manufacturing and/or sale of the Licensed Products, and particularly including, without limitation, such license to develop and have developed, make and have made, use and have used, sell and have sold, offer for sale and have offered for sale, import and have imported, export and have exported Licensed Products, which license shall be exclusive even as to Licensor, and

(b) the right to grant bona fide sublicenses to third parties, to develop and have developed, to make and have made, use and have used, sell and have sold, import and have imported, export and have exported, Licensed Products, and to exercise all other rights under the License; provided, however, Licensee shall not have the right to grant any sublicense or to transfer any of its rights under the License unless each such sublicense or other transfer granted by Licensee contains terms and conditions under which the Sublicensee or transferee will be bound in the same manner as Licensee is under this Agreement. A copy of the proposed agreement shall be provided to Licensor prior to the execution of the Agreement.

License Property
Lcensed Products shall mean any and all products comprising tablets with Cannabinoids) utilizing the Licensed Technology for the delivery of a recreational, Medicinal or Pharmaceutical Cannabinoids product in specific dosage forms.

Cannabinoids means any of the chemical compounds that are the active components of the Cannabis genus of plants and its three species, Cannabis sativa, Cannabis indica, and Cannabis ruderalis; whether the compounds are synthetically produced or plant-derived, as well as cannabinoid compounds, formulations or products, that include single and/or multiple Cannabinoids including both synthetic and plant-derived Cannabinoids, as well as any and all Cannabinoid analogues. For formulations or compounds which may include combinations of API’s, other than Cannabinoids or terpenes, it is being agreed that if the API is another FDA approved Pharmaceutical, Licensor approval will be required to ensure that the API is not the subject of a current Licensor product, or the product of another licensee of the Licensor.

Medicinal shall mean any product containing marijuana, hemp or cannabis produced and sold for health, wellness, or nutritional purposes, including as herbal medicine, including products produced or sold through U.S. state-licensed or regulated marijuana programs and comparable programs in other countries and jurisdictions.

Licensed Technology shall mean the aggregate of the Licensed Inventions, the Licensed Know-how, the Licensed Products and the Licensed Patents and any other information and/or technology related to the Licensed Products and/or the design and/or the manufacturing of the Licensed Products

Licensed Patents shall mean any and all rights arising out of or resulting from (i) the patents and patent application set forth in Schedule 1.14 attached to this Agreement, as well as any additional patents or patent applications related to any aspect of any Licensed Technology Improvements, Licensed Know-how, Licensed Products, and/or Licensed Technology (as herein defined) filed prior to or during the term of this Agreement and (ii) any patent granted in respect of all such applications, as well as, without limitation, any substitutions, divisions, continuations, continuations-in-part, reissues, renewals, re-examinations, extensions, supplementary protection certificates, confirmations, registrations, revalidations and the like, of any and all such patents and patent applications and any international equivalents thereof.

Field of Use
Licensed Field shall mean the use of Cannabinoids, together with the Licensed Technology for recreational, Medicinal and Pharmaceutical purposes in humans and animals.

IPSCIO Record ID: 384961

License Grant
By this agreement, for the Clinical Development of product candidates, Licensee may chose Product Candidates, if any, for Clinical Development. Licensee of Japan shall notify Licensor of the United Kingdom in writing of whether it is has chosen one or more Product Candidates.

Upon notice by Licensee to Licensor from time to time during the period permitted therefor pursuant to this Agreement, Licensor shall granted to Licensee under Collaboration IP and Licensor Background IP, without the need for further action by either of the Parties, an exclusive, license to make, have made, use, offer for sale, sell, import and otherwise exploit the Product Candidates referenced in such notices in the Territory in the Research Field.

Licensor of the United Kingdom grants to the Licensee of Japan under Licensor Background IP and Collaboration IP, the sole right to use the same in any way whatsoever for the purpose of the Research Collaboration including to research and use Research Compounds for the purposes necessary to perform its obligations and exercise its rights under the Research Plan but excluding the right to manufacture Research Compounds or have Research Compounds manufactured on its
behalf other than by Licensor. This right shall not be capable of sub-license.

License Property
Licensor has expertise in the research and development of pharmaceutical preparations based upon botanical extracts from chemovars of Cannabis sativa, and, has proprietary knowledge and interests in the research and development of pharmaceutical preparations based upon botanical extracts from different chemovars of Cannabis sativa in addition to that combination of botanical extracts used in SATIVEXâ„¢ oromucosal spray.

Research Compounds shall mean collectively, all Selected BDCs and Selected Drug Candidates. For clarity, Research Compounds shall include Synthetic Cannabinoids synthesized under the Research Plan and which subsequently become Selected BDCs and/or Selected Drug Candidates.

Botanical Drug Candidate or BDC shall mean
—  any cannabinoid from a single chemovar of a chemically and genetically characterized Cannabis sativa plant (Phytocannabinoid) at any stage of research or development made using any extraction method and in any degree of purification in which only a single cannabinoid is present in a concentration which has the potential to be therapeutically active including, without limitation, the THC fraction and the CBD fraction separately; and
—  a combination of two or more Phytocannabinoid extracts described containing two or more Phytocannabinoids present in concentrations such that both have the potential to be therapeutically active mixed in a precise ratio i.e. the THC and CBD fractions mixed (without other fractions) in the ratio of THC CBD of 90 10. For clarity specifically excluded from the definition of BOC is any combination of the THC and CBD fractions when mixed (without other fractions) in a ratio of CBD to THC that falls inside the range of 2575 to 7525; and
— any biological or chemical modification of the Phytocannabinoids including any metabolite or degradant.

Synthetic Cannabinoid shall mean any Phytocannabinoid produced by synthetic methods either pursuant to a Research Plan (a Type 1 Synthetic Cannabinoid), or, outside of the Research Collaboration but with information resulting from the Research Collaboration (Type 2 Synthetic
Cannabinoid).

Synthetic Cannabinoid Product shall mean any pharmaceutical product containing a Type 1 Synthetic Cannabinoid (Type 1 Synthetic Product) or a Type 2 Synthetic Cannabinoid (Type 2 Synthetic Cannabinoid Product).

Synthetic Molecule shall mean a synthetic molecule whose chemistry is not based on a Phytocannabinoid but;
—  which has been developed with information resulting from the Research Collaboration and,
—  for which one or more patent· applications have been filed by Licensee on an invention conceived within three years following expiration of the Research Term or any Extended Research Term claiming a novel composition of matter and a cannabinomimetic or cannabinergic effect through direct, or indirect (i.e. modulation of related metabolic enzyme systems), effects on one or more cannabinoid receptors (including their allosteric sites).

Synthetic Molecule Product shall mean any pharmaceutical product containing a Synthetic Molecule.

Field of Use
The field of use is neuropsychopharmacology, with special reference to schizophrenia, cannabinoid/opioid analgesic combinations, and, oncology.

Research Field shall mean the treatment, diagnosis, prevention, or palliation of diseases, conditions, syndromes, and maladies of the central and peripheral nervous. systems of humans and animals and cancer in humans and animals.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.